ESPOIR and the French database management: what have we learned from the first years of follow-up?

被引:0
|
作者
Combe, B. [1 ]
机构
[1] Univ Montpellier, Hop Lapeyronie, Dept Rhumatol, F-34059 Montpellier, France
关键词
ESPOIR cohort; rheumatoid arthritis; early arthritis; undifferentiated arthritis; outcome; EARLY RHEUMATOID-ARTHRITIS; RECENT-ONSET POLYARTHRITIS; RADIOGRAPHIC PROGRESSION; CLASSIFICATION CRITERIA; EROSIVE DISEASE; COHORT; EQ-5D; RA; RECOMMENDATIONS; METHOTREXATE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ESPOIR (Etude et Suivi des POlyarthrites Indifferenciees Recentes) is a multicentre national cohort sponsored by the French Society for Rheumatology. The patients had early arthritis (< 6-month disease duration), had a certain/probable clinical diagnosis of RA or undifferentiated arthritis potentially becoming RA and were DMARDs or glucocorticoids naive. ESPOIR is a cohort of early arthritis, highly enriched for rheumatoid arthritis (RA) patients, since in patients followed for 5 years more than 90% met ACR/EULAR criteria for RA. A total of 813 patients were enrolled between December 2002 and March 2005 in 14 academic regional centres with the participation of a network of private rheumatologists. Today, 104 clinical research projects have been selected by the scientific committee of the cohort. The projects focus on data from the first 5 years of follow-up. Many studies are in progress, and 54 original articles have been published. The research projects cover a wide range of topics, including environmental factors, diagnosis, evolution, and prognosis, evaluation of disease, imaging, genetics, biomarkers, medical economics and therapeutic strategies.
引用
收藏
页码:S153 / S157
页数:5
相关论文
共 50 条
  • [31] What have we learned from cancer immunotherapy in the last 3 years?
    Ascierto, Paolo A.
    Marincola, Francesco M.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
  • [32] Dopamine and addiction: what have we learned from 40 years of research
    Solinas, Marcello
    Belujon, Pauline
    Fernagut, Pierre Olivier
    Jaber, Mohamed
    Thiriet, Nathalie
    JOURNAL OF NEURAL TRANSMISSION, 2019, 126 (04) : 481 - 516
  • [33] What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients - Discussion
    Dunn, DL
    Fung, JJ
    Dafoe, DC
    Levy, M
    ANNALS OF SURGERY, 1999, 230 (03) : 448 - 449
  • [34] Pain management today—what have we learned?
    Richard M. Langford
    Clinical Rheumatology, 2006, 25 : 2 - 8
  • [35] Pain management today - what have we learned?
    Langford, Richard M.
    CLINICAL RHEUMATOLOGY, 2006, 25 (Suppl 1) : S2 - S8
  • [36] PRECISION FEED MANAGEMENT - WHAT HAVE WE LEARNED?
    Chase, L. E.
    2018 CORNELL NUTRITION CONFERENCE FOR FEED MANUFACTURERS, PROCEEDINGS, 2018, : 222 - 228
  • [37] CFIRP: What we learned in the first ten years
    Chambers, CL
    McComb, WC
    Tappeiner, JC
    Kellogg, LD
    Johnson, RL
    Spycher, G
    FORESTRY CHRONICLE, 1999, 75 (03): : 431 - 434
  • [38] Two years of COVID-19 and tourism: what we learned, and what we should have learned
    Goessling, Stefan
    Schweiggart, Nadja
    JOURNAL OF SUSTAINABLE TOURISM, 2022, 30 (04) : 915 - 931
  • [39] What Have We Learned From Antibiotics?
    Smith, James Leif
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (08) : 1183 - 1183
  • [40] What We Have Learned from Helioseismology
    Michael J. Thompson
    Astrophysics and Space Science, 1998, 261 : 23 - 34